This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Boniva

Roche Holding AG

Drug Names(s): ibandronate sodium, Bonviva (extended dosing), Bondronat (EU), Bondenza (EU), RG484, Ro200-540iv, Ro-200-5450po, CT-064 (JP)

Description: Roche no longer reports revenue as of Q1 2013.

BONIVA (ibandronate sodium) is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. In osteoporosis, where osteoclasts break down bone too quickly, inhibition of this pathway has been shown to slow bone turnover, leading to not only an attenuation of turnover but also a mean increase in bone mass.

In 2003, the FDA approved once-daily Boniva. Boniva is indicated for the treatment and prevention of osteoporosis in postmenopausal women. The recommended dose of Boniva is 2.5 mg (oral tablet) once daily.

In March 2005, Boniva received approval in a new formulation, as a once-monthly oral tablet, with a recommended dosage of 150 mg on the same date each month.

Deal Structure: Revenue splits for this drug are BioMedTracker estimates.

In December 2001, Roche and GSK announced that they would co-develop and co-promote Boniva for the treatment and prevention of postmenopausal osteoporosis in all countries, except Japan. Under the terms of the agreement, Roche and GSK will share the development and registration costs for the product and Roche will receive certain milestone payments from GSK. Roche will account for all sales of the product, both companies will share profits.

On Sept 12, 2006 Chugai Pharmaceutical announced that it entered into an agreement with Taisho Pharmaceutical to co-develop and co-market R484 (Boniva), a bisphosphonate which Chugai is currently developing in Japan for the treatment of osteoporosis. Under the agreement, Chugai will co-develop and co-market the compound with Taisho. Chugai will receive an upfront fee and milestone payments from Taisho.

In June 2011, Nycomed announced that it has completed the transfer of marketing...See full deal structure in Biomedtracker

Partners: GlaxoSmithKline plc Chugai Pharmaceutical Co., Ltd. Taisho Pharmaceutical Co., Ltd.


Boniva News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug